§ Federal grant opportunity · PAR-25-101
Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional)
National Institutes of Health is accepting applications for Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional). The deadline is August 11, 2027 and the published award range is $150K.
Key facts
- Funder
- National Institutes of Health
- Application deadline
- August 11, 2027
- Award range
- $150K
- Eligibility
- Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
- Geography
- United States
- Focus areas
- Education, Health
- Opportunity number
- PAR-25-101
Program overview
The National Institute on Drug Abuse (NIDA) Cutting-Edge Basic Research Award (CEBRA) is designed to foster highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs). It supports high-risk and potentially high-impact research that is sparse or not included in NIDA's current portfolio that has the potential to transform SUD research. The proposed research should: 1. develop, and/or adapt, revolutionary techniques or methods for addiction research or that show promising future applicability to SUD research; and /or 2. test an innovative and significant hypothesis for which there are scant precedent or preliminary data and which, if confirmed, would transform current thinking.
How to apply
- Confirm your organization meets the eligibility criteria above.
- Read the full funding opportunity announcement from National Institutes of Health.
- Draft your narrative against the funder's stated priorities and review criteria.
- Submit before August 11, 2027, allowing time for registration and validation.
Related grant opportunities
- Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
- WaterSMART: Desalination Construction Projects
- Title XVI Water Reclamation and Reuse Projects
- US Army Combat Capabilities Development Command (DEVCOM) Indo-Pacific Fundamental Research Collaboration Opportunities
- Advancement and Innovation in Measurement of Language Development and Predictors (R01 Clinical Trial Not Allowed)
Find every grant your organization qualifies for
Mavenly scores this opportunity against your mission, geography, and funding history — then drafts the proposal with you and tracks the deadline through submission and reporting.